MétaCan
Menu
Back to cohort
Record W4397007666 · doi:10.1016/j.esmoop.2024.103102

114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study

2024· article· en· W4397007666 on OpenAlexaff
Christian Jackisch, S-A. Im, André Mattar, Daniil Stroyakovskiy, Zbigniew Nowecki, Michelino De Laurentiis, J-Y Pierga, Kyung Hae Jung, Christian Schem, Sarah Heeson, Veronica Craine, Bing Wang, Eleonora Restuccia, Antoinette R. Tan

Bibliographic record

VenueESMO Open · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsRoche (Canada)
Fundersnot available
KeywordsPertuzumabTrastuzumabMedicineOncologyChemotherapyFixed-dose combinationBreast cancerPharmacologyInternal medicineCancer

Abstract

fetched live from OpenAlex

The primary analysis of the FeDeriCa study (NCT03493854; Tan AR, et al. Lancet Oncol 2021) showed that PH FDC SC cycle 7 P and H serum trough concentrations were non-inferior to intravenous (IV) P and H, with comparable total pathological complete response rates and safety profiles when given as neoadjuvant therapy for HER2-positive EBC. Here we report long-term efficacy and safety data. Patients (pts) had HER2-positive operable, locally advanced or inflammatory stage II–IIIC BC and left ventricular ejection fraction ≥55%. They received eight cycles of neoadjuvant chemotherapy (one of two standard regimens chosen by the investigator) + P IV (840 mg loading dose then 420 mg maintenance) + H IV (8 mg/kg then 6 mg/kg) or PH FDC SC (1200 mg P/600 mg H then 600 mg each as FDC SC) every 3 weeks during cycles 5–8 in a 1:1 randomisation design. Pts continued adjuvant HER2-targeted treatment after surgery, per randomisation, to complete 18 cycles. Secondary endpoints included invasive disease-free survival (iDFS), event-free survival (EFS), distant recurrence-free interval (DRFI), overall survival (OS) and safety (focusing on cardiac adverse events). Data cut-off was 2 Jun, 2023; median follow-up was 51.4 months in the P + H IV arm and 51.2 months in the PH FDC SC arm. Long-term efficacy data are shown in the table. No new safety signals, including for cardiac safety, were observed.Table: 114PP + H IV n = 252PH FDC SC n = 248iDFSPts who underwent surgery, n239234Pts with event, n (%)23 (9.6)26 (11.1)Unstratified hazard ratio (HR)(95% confidence interval [CI])1.13 (0.64, 1.97)4-year event-free rate (95% CI)89.5 (85.4, 93.6)88.5 (84.3, 92.7)EFSPts, n252248Pts with event, n (%)29 (11.5)32 (12.9)HR (95% CI)1.20 (0.72, 1.98)4-year event-free rate (95% CI)88.5 (84.4, 92.5)86.6 (82.2, 90.9)DRFIPts, n252248Pts with event, n (%)18 (7.1)19 (7.7)HR (95% CI)1.17 (0.61, 2.24)4-year event-free rate (95% CI)92.5 (89.2, 95.8)91.9 (88.4, 95.4)OSPts, n252248Pts with event, n %12 (4.8)14 (5.6)HR (95% CI)1.26 (0.58, 2.72)4-year event-free rate (95% CI)95.5 (92.9, 98.1)94.1 (91.1, 97.1) Open table in a new tab The long-term efficacy of PH FDC SC was comparable to that of P + H IV. Safety remained similar to P + H IV and consistent with P + H + chemotherapy. Overall, these findings support the primary analysis results. PH FDC SC is established as a faster, more convenient, less invasive, pt- and healthcare professional-preferred alternative to P + H IV for pts with HER2-positive BC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.637
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.331
Teacher spread0.317 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicBreast Cancer Treatment StudiesFrench-language works237,207